Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (92 total)
-
Creator: Chappell, Keith J., Francesca L. Mordant, Zheyi Li, Danushka K. Wijesundara, Paula Ellenberg, Julia A. Lackenby, Stacey T. M. Cheung, Naphak Modhiran, Michael S. Avumegah, Christina L. Henderson, Kym Hoger, Paul Griffin, Jillian Bennet, Luca Hensen,…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-19
Description: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential… -
Creator: Goepfert, Paul A., Bo Fu, Anne-Laure Chabanon, Matthew I. Bonaparte, Matthew G. Davis, Brandon J. Essink, Ian Frank, Owen Haney, Helene Janosczyk, Michael C. Keefer, Marguerite Koutsoukos, Murray A. Kimmel, Roger Masotti, Stephen J. Savarino, Lode…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-19
Description: CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM… -
Creator: Hacisuleyman, Ezgi, Caryn Hale, Yuhki Saito, Nathalie E. Blachere, Marissa Bergh, Erin G. Conlon, Dennis J. Schaefer-Babajew, Justin DaSilva, Frauke Muecksch, Christian Gaebler, Richard Lifton, Michel C. Nussenzweig, Theodora Hatziioannou, Paul D.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-21
Description: Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks… -
Creator: Greinacher, Andreas, Thomas Thiele, Theodore E. Warkentin, Karin Weisser, Paul A. Kyrle, and Sabine Eichinger.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1… -
Creator: Schultz, Nina H., Ingvild H. Sørvoll, Annika E. Michelsen, Ludvig A. Munthe, Fridtjof Lund-Johansen, Maria T. Ahlen, Markus Wiedmann, Anne-Hege Aamodt, Thor H. Skattør, Geir E. Tjønnfjord, and Pål A. Holme.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). -
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). -
Creator: the Oxford COVID-19 Vaccine Trial Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-30
Description: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Creator: Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: Benenson, Shmuel, Yonatan Oster, Matan J. Cohen, and Ran Nir-Paz.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: The surge of coronavirus disease 2019 (Covid-19) around the world and the need for urgent and intensive medical care have weighed heavily on health care systems and hospitals.Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: Ella, Raches, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-08
Description: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled…